Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Pattern of recurrence after stereotactic body radiotherapy for para-aortic oligo-recurrent prostate cancer, a multicentric analysis.
Francolini G, Garlatti P, Di Cataldo V, Triggiani L, Simoni N, Detti B, Lorenzetti V, Colombo F, Morelli V, Ganovelli M, Caprara L, Orsatti C, Burchini L, Frosini G, Bertini N, Loi M, Simontacchi G, Greto D, Desideri I, Meattini I, Livi L. Francolini G, et al. Among authors: morelli v. Radiol Med. 2023 Nov;128(11):1423-1428. doi: 10.1007/s11547-023-01701-x. Epub 2023 Aug 19. Radiol Med. 2023. PMID: 37597125
'Le Roi est mort, vive le Roi': New Roles of Radiotherapy in the Treatment of Lymphomas in Combination With Immunotherapy.
Guerini AE, Filippi AR, Tucci A, Simontacchi G, Re A, Guaineri A, Morelli V, Borghetti P, Triggiani L, Pegurri L, Pedretti S, Volpi G, Spiazzi L, Magrini SM, Buglione M. Guerini AE, et al. Among authors: morelli v. Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):e135-e148. doi: 10.1016/j.clml.2021.09.005. Epub 2021 Sep 10. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34728169 Review.
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial.
Bonù ML, Magli A, Tomasini D, Frassine F, Albano D, Arcangeli S, Bruni A, Ciccarelli S, De Angeli M, Francolini G, Franzese C, Ghirardelli P, Grazioli L, Guerini A, Lancia A, Marvaso G, Sepulcri M, Trodella LE, Morelli V, Georgopulos A, Domina AO, Granello L, Mataj E, Barbera F, Triggiani L. Bonù ML, et al. Among authors: morelli v. BJR Open. 2022 Nov 29;4(1):20220032. doi: 10.1259/bjro.20220032. eCollection 2022. BJR Open. 2022. PMID: 38525170 Free PMC article.
Anal squamous cell carcinoma: Impact of radiochemotherapy evolution over years and an explorative analysis of MRI prediction of tumor response in a mono-institutional series of 131 patients.
Bonù ML, La Mattina S, Singh N, Toraci C, Spiazzi L, Terraneo F, Barbera F, Vitali P, Frassine F, Guerini A, Triggiani L, Tomasini D, Morelli V, Imbrescia J, Andreuccetti J, Frittoli B, Pittiani F, Grazioli L, Portolani N, Nicosia L, Albano D, Bertagna F, Magrini SM, Buglione M. Bonù ML, et al. Among authors: morelli v. Front Oncol. 2022 Oct 24;12:973223. doi: 10.3389/fonc.2022.973223. eCollection 2022. Front Oncol. 2022. PMID: 36353538 Free PMC article.
Early results of PRO-EPI: PROspective multicenter observational study on elective pelvic nodes irradiation in patients with intermediate/high/very high-risk non-metastatic prostate cancer submitted to radical, adjuvant, or salvage radiotherapy with or without concomitant androgen deprivation therapy.
Guerini AE, Noale M, Mortellaro G, Lisi R, Bruni A, Santini R, Muto P, Ferrera G, Cossali G, Morelli V; PRO-EPI study group; Magrini SM, Spiazzi L, Buglione M. Guerini AE, et al. Among authors: morelli v. Front Oncol. 2022 Nov 2;12:951220. doi: 10.3389/fonc.2022.951220. eCollection 2022. Front Oncol. 2022. PMID: 36408148 Free PMC article.